ABIONYX PHARMA SA (ABNX.PA) Stock Analyst Earnings Estimates
EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 675K | 5.252M 678.07% | 4.64M -11.65% | 4.692M 1.12% | 4.692M | 12.138M 158.70% | |
| EBITDA YoY % growth | -5.833M -98.00% | -3.974M 31.87% | -3.259M 17.99% | -4.896M -50.23% | -8.568M -75.00% | -6.222M 27.38% | |
| EBIT YoY % growth | -5.952M -100.54% | -4.109M 30.96% | -3.412M 16.96% | -5.508M -61.43% | -9.18M -66.67% | -6.834M 25.56% | |
| Operating Margin | -881.78% | -78.24% | -73.53% | -117.39% | -195.65% | -56.30% | |
| EPS YoY % growth | N/A 25.58% | N/A -25.00% | N/A 10.00% | -0.14 22.22% | -0.21 -50.00% | -0.15 28.57% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 2.344M 10.15% | % | ||
| Q4 2023 Q2Q % growth | 2.512M -4.20% | % | ||
| Q2 2023 Q2Q % growth | 2.128M -19.09% | % | ||
| Q4 2022 Q2Q % growth | 2.622M 304.63% | % | ||
| Q2 2022 Q2Q % growth | 2.63M 9,640.74% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 0% |
| Revenue | N/A | N/A | 0% | 0% |